Advisors Preferred LLC Acquires New Position in Privia Health Group, Inc. $PRVA

Advisors Preferred LLC acquired a new position in shares of Privia Health Group, Inc. (NASDAQ:PRVA) during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 82,458 shares of the company’s stock, valued at approximately $1,696,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Durable Capital Partners LP boosted its position in Privia Health Group by 1.8% during the third quarter. Durable Capital Partners LP now owns 11,691,685 shares of the company’s stock worth $291,123,000 after purchasing an additional 203,842 shares in the last quarter. State Street Corp boosted its position in shares of Privia Health Group by 1.5% in the 2nd quarter. State Street Corp now owns 4,171,069 shares of the company’s stock worth $95,935,000 after buying an additional 61,853 shares in the last quarter. Van Berkom & Associates Inc. boosted its position in shares of Privia Health Group by 1.8% in the 4th quarter. Van Berkom & Associates Inc. now owns 3,844,256 shares of the company’s stock worth $91,147,000 after buying an additional 69,691 shares in the last quarter. Geode Capital Management LLC grew its stake in Privia Health Group by 1.1% in the 4th quarter. Geode Capital Management LLC now owns 2,814,290 shares of the company’s stock valued at $66,738,000 after acquiring an additional 31,204 shares during the last quarter. Finally, Principal Financial Group Inc. grew its stake in Privia Health Group by 1.6% in the 4th quarter. Principal Financial Group Inc. now owns 2,787,802 shares of the company’s stock valued at $66,099,000 after acquiring an additional 43,589 shares during the last quarter. 94.48% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Privia Health Group

In other Privia Health Group news, CFO David Mountcastle sold 24,734 shares of the business’s stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $27.50, for a total value of $680,185.00. Following the completion of the transaction, the chief financial officer directly owned 186,728 shares in the company, valued at approximately $5,135,020. The trade was a 11.70% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Matthew Shawn Morris sold 88,110 shares of the stock in a transaction on Friday, June 26th. The stock was sold at an average price of $25.33, for a total value of $2,231,826.30. Following the transaction, the director directly owned 76,651 shares in the company, valued at approximately $1,941,569.83. This represents a 53.48% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 478,855 shares of company stock worth $12,099,109. Insiders own 5.70% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on PRVA shares. Barclays cut their target price on shares of Privia Health Group from $25.00 to $24.00 and set an “equal weight” rating for the company in a research report on Tuesday, May 26th. Evercore set a $26.00 price target on shares of Privia Health Group in a research report on Wednesday, April 8th. Weiss Ratings raised shares of Privia Health Group from a “hold (c-)” rating to a “hold (c)” rating in a research note on Thursday, July 2nd. Zacks Research downgraded Privia Health Group from a “hold” rating to a “strong sell” rating in a research report on Tuesday, July 7th. Finally, Canaccord Genuity Group reduced their target price on Privia Health Group from $35.00 to $34.00 and set a “buy” rating on the stock in a research note on Friday, May 8th. Eleven research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $31.15.

Privia Health Group Stock Performance

Shares of PRVA opened at $28.03 on Wednesday. Privia Health Group, Inc. has a 1 year low of $18.77 and a 1 year high of $28.30. The company’s 50 day simple moving average is $23.90 and its 200 day simple moving average is $23.19. The company has a market capitalization of $3.53 billion, a price-to-earnings ratio of 175.20, a PEG ratio of 2.21 and a beta of 0.83.

Privia Health Group Company Profile

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.